Tolvaptan should be used very carefully in very elderly patients.
作者信息
Kahraman Fatih, Yılmaz Ahmet Seyda
机构信息
Department of Cardiology, Düzce Atatürk State Hospital; Düzce-Turkey.
出版信息
Anatol J Cardiol. 2018 Jan;19(1):79. doi: 10.14744/AnatolJCardiol.2017.8195.
Abstract
摘要
相似文献
1
Tolvaptan should be used very carefully in very elderly patients.托伐普坦在高龄患者中应极其谨慎地使用。
Anatol J Cardiol. 2018 Jan;19(1):79. doi: 10.14744/AnatolJCardiol.2017.8195.
2
Efficacy and safety of the early use of V2 receptor antagonists in elderly patients with decompensated heart failure.V2受体拮抗剂早期用于老年失代偿性心力衰竭患者的疗效与安全性
Heart Vessels. 2018 Feb;33(2):145-154. doi: 10.1007/s00380-017-1039-7. Epub 2017 Aug 16.
3
Effects of tolvaptan on congestive heart failure complicated with chylothorax in a neonate.托伐普坦对新生儿充血性心力衰竭合并乳糜胸的影响。
Pediatr Int. 2015 Oct;57(5):1020-2. doi: 10.1111/ped.12697. Epub 2015 Sep 10.
4
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.口服托伐普坦对因心力衰竭加重而住院患者的影响：EVEREST结局试验
JAMA. 2007 Mar 28;297(12):1319-31. doi: 10.1001/jama.297.12.1319. Epub 2007 Mar 25.
5
[The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia].托伐普坦治疗心力衰竭合并低钠血症患者的疗效与安全性
Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Oct;39(10):936-40.
6
Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size.急性失代偿性心力衰竭患者使用托伐普坦治疗的反应者的临床特征：保留肾脏大小的重要性。
J Cardiol. 2016 Feb;67(2):177-83. doi: 10.1016/j.jjcc.2015.04.017. Epub 2015 Jun 10.
7
Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.托伐普坦对急性失代偿性心力衰竭合并慢性肾脏病患者的临床疗效
Heart Vessels. 2016 Oct;31(10):1643-9. doi: 10.1007/s00380-015-0775-9. Epub 2015 Nov 28.
8
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.血管加压素拮抗剂托伐普坦对心力衰竭加重住院患者的影响：一项随机对照试验。
JAMA. 2004 Apr 28;291(16):1963-71. doi: 10.1001/jama.291.16.1963.
9
Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.考虑肾素-血管紧张素-醛固酮系统与精氨酸加压素相互作用时托伐普坦对慢性心力衰竭患者的反应预测及影响
Int Heart J. 2016 Jul 27;57(4):461-5. doi: 10.1536/ihj.15-491. Epub 2016 Jun 29.
10
Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure.对于失代偿性心力衰竭患者，早期使用V2受体拮抗剂与缩短住院时间及降低院内死亡率相关。
Heart Vessels. 2016 Oct;31(10):1650-8. doi: 10.1007/s00380-015-0780-z. Epub 2015 Dec 16.
本文引用的文献
1
Tolvaptan in the very elderly with acute decompensated heart failure- a therapeutic option worth of consideration.托伐普坦用于老年急性失代偿性心力衰竭患者——一种值得考虑的治疗选择。
Anatol J Cardiol. 2017 Sep;18(3):213-214. doi: 10.14744/AnatolJCardiol.2017.8033.
2
Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure.托伐普坦早期用于高龄急性失代偿性心力衰竭患者的临床效用
Anatol J Cardiol. 2017 Sep;18(3):206-212. doi: 10.14744/AnatolJCardiol.2017.7628. Epub 2017 Aug 2.
3
Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.托伐普坦在因慢性心力衰竭加重伴严重低钠血症住院患者中的应用：土耳其一家单中心的初步经验。
Turk Kardiyol Dern Ars. 2017 Jul;45(5):415-425. doi: 10.5543/tkda.2017.80026.
4
Total water intakes of community-living middle-old and oldest-old adults.社区生活的中老年和高龄老年人的总水摄入量。
J Gerontol A Biol Sci Med Sci. 2009 Apr;64(4):481-6. doi: 10.1093/gerona/gln045. Epub 2009 Feb 12.
5
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.口服托伐普坦对因心力衰竭加重而住院患者的影响：EVEREST结局试验
JAMA. 2007 Mar 28;297(12):1319-31. doi: 10.1001/jama.297.12.1319. Epub 2007 Mar 25.
Zotero 插件